CAR-T Cell Therapy in Non-Hodgkin Lymphoma: Clinical Trial Landscape Review

360 eligible clinical trials for CAR-T therapy in non-Hodgkin lymphoma were analyzed from the Trialtrove database up to December 18, 2025. The review, authored by Jinyu Wu and published on figshare, describes the global trial landscape, including characteristics like trial status, phase, location, and targets. The document was last updated on May 8, 2026.

Use Cases

• Analyzing the geographic distribution and sponsor types of CAR-T trials based on the described trial characteristics.
• Tracking the diversification of molecular targets beyond CD19 based on the landscape analysis.
• Reviewing the prioritization of safety versus long-term efficacy endpoints based on the reported study endpoints.
• Identifying unmet needs and future research directions in CAR-T therapy based on the conclusions of the review.

Strengths

• Analysis is based on 360 clinical trials, providing a substantial sample size for the landscape review.
• Systematic methodology using the Trialtrove database with predefined search and screening criteria.
• Clear temporal scope with trials registered up to December 18, 2025.

Limitations

• The dataset is a 36.7 KB DOCX document, which is a text-based review rather than a structured data file.
• Row count and column-level documentation are absent; the analysis is presented in narrative form.
• Data freshness should be verified as the underlying trial data cutoff was December 2025.

Provenance

Source

Trialtrove database, analysis by Jinyu Wu.

Collection Method

Systematic landscape analysis of interventional trials using predefined search and screening criteria.

Time Range

Trials registered up to December 18, 2025.

Freshness

Last updated 2026-05-08 05:48:17

Geography

Global, with concentration noted in a limited number of countries.